Estimated effects of amyloid reduction on cognitive change: A Bayesian update across a range of priors
出版年份 2023 全文链接
标题
Estimated effects of amyloid reduction on cognitive change: A Bayesian update across a range of priors
作者
关键词
-
出版物
Alzheimers & Dementia
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2023-10-31
DOI
10.1002/alz.13470
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Lecanemab trial in AD brings hope but requires greater clarity
- (2023) Madhav Thambisetty et al. Nature Reviews Neurology
- Need for truthfulness in dementia research
- (2023) Timothy P Daly BMJ-British Medical Journal
- Alzheimer’s disease: FDA approves lecanemab amid cost and safety concerns
- (2023) Elisabeth Mahase BMJ-British Medical Journal
- Unblinding in the lecanemab trial in Alzheimer's disease
- (2023) Willem A Van Gool BRAIN
- Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs
- (2023) Francesca Alves et al. NEUROLOGY
- Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?
- (2023) Vincent Planche et al. JAMA Neurology
- Donanemab in Early Symptomatic Alzheimer Disease
- (2023) John R. Sims et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
- (2022) Eric Karran et al. NATURE REVIEWS DRUG DISCOVERY
- Ventricular enlargement caused by aducanumab
- (2022) Scott Ayton Nature Reviews Neurology
- Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable meta‐analysis
- (2022) Menglan Pang et al. Alzheimers & Dementia
- High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects
- (2022) N. Villain et al. REVUE NEUROLOGIQUE
- High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France
- (2022) N. Villain et al. REVUE NEUROLOGIQUE
- An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer’s Disease
- (2022) Timothy Daly et al. AJOB Neuroscience
- Comment on “Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An updated instrumental variable meta‐analysis”
- (2022) Sarah F Ackley et al. Alzheimers & Dementia
- Relationship between beta‐amyloid (Ab) plaque reduction and clinical benefit: the rationale for aducanumab approval
- (2022) Yaning Wang Alzheimers & Dementia
- Lecanemab in Early Alzheimer’s Disease
- (2022) Christopher H. van Dyck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies
- (2022) Bruno P. Imbimbo et al. PHARMACOLOGICAL RESEARCH
- Lecanemab trial finds slight slowing of cognitive decline, but clinical benefits are uncertain
- (2022) Elisabeth Mahase BMJ-British Medical Journal
- Lecanemab for Alzheimer’s disease
- (2022) Sebastian Walsh et al. BMJ-British Medical Journal
- Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
- (2021) Sarah F Ackley et al. BMJ-British Medical Journal
- Instrumental variable meta-analysis of aggregated randomized drug trial data for evaluating proposed target mechanisms
- (2021) Sarah F Ackley et al. BMJ-British Medical Journal
- Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease
- (2021) Konstantinos I. Avgerinos et al. AGEING RESEARCH REVIEWS
- Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease
- (2021) Edo Richard et al. Alzheimers & Dementia
- Cognitive outcomes of anti‐amyloid‐β monoclonal antibodies in patients with Alzheimer's disease: A systematic review and meta‐analysis of randomized controlled trials
- (2021) Paulo Eduardo Lahoz Fernandez et al. Alzheimers & Dementia
- What the Aducanumab Approval Reveals About Alzheimer Disease Research
- (2021) Jennifer J. Manly et al. JAMA Neurology
- Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL
- (2018) Pierrick Bourgeat et al. NEUROIMAGE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started